Identifying Combination Therapies in Ovarian Tumors using High Throughput Dynamic BH3 Profiling
使用高通量动态 BH3 分析确定卵巢肿瘤的联合疗法
基本信息
- 批准号:10307520
- 负责人:
- 金额:$ 6.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-12-01 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAnimal ExperimentsAnimal ModelApoptosisApoptoticAscitesBiologicalBiological AssayCancer EtiologyCancer ModelCancer PatientCarboplatinCell Death Signaling ProcessCellsCessation of lifeChemicalsClassificationClinicalCombined Modality TherapyDataDependenceDiagnosisDiseaseDoxorubicinDrug CombinationsEducational workshopEnsureEnvironmentExcisionExposure toFeedbackFoundationsGeneticGoalsGrantGraphHourImmunoprecipitationLaboratoriesLeadLibrariesLiquid substanceMaintenance TherapyMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMapsMass Spectrum AnalysisMeasuresMediatingMitochondriaModelingMolecularMolecular TargetOrganoidsOutcomePaclitaxelPathway interactionsPatient SelectionPatientsPharmaceutical PreparationsPharmacologyPhenotypePlatinumPopulationPrimary NeoplasmProbabilityProteinsRecurrent diseaseRegimenResearchResearch PersonnelResearch TrainingResistanceSamplingSolid NeoplasmTechniquesTechnologyTestingTumor Cell LineTumor-DerivedUnited StatesValidationWomanWorkXenograft Modelbasecancer cellcancer therapycareercell killingchemotherapycombinatorialcytotoxicdimerdrug candidatehigh throughput screeningimprovedin vivoinhibitorinnovationmeetingsmimeticsneoplastic cellnovelnovel strategiesovarian neoplasmpatient derived xenograft modelpatient populationpatient responseprecision medicinepro-apoptotic proteinrelapse patientsresponsesimulationsmall molecule librariesstandard of carestatisticssuccesssymposiumtargeted agenttreatment responsetumortumor heterogeneitytumor xenograft
项目摘要
Project Summary/Abstract
Ovarian cancer is the fifth leading cause of cancer deaths overall in women. The most recent estimates
indicate that over 20,000 new cases will be diagnosed this year and nearly 14,000 women will die of the
disease in the US in 2019 alone. The platinum-based standard of care cytotoxic regimen has remained largely
stagnant for the last 15 years and recurrent disease is frequently platinum-resistant. Despite some recent
success using molecular targeted agents and maintenance therapies (such as PARP inhibitors), the genetic
complexity and lack of common molecular drivers make predicting patient responses difficult. Additionally, in
relapsed patients, molecular changes induced by cancer therapies are multifaceted. Combining multiple drugs
to treat ovarian cancer may be the most direct path to overcoming this intra-tumoral heterogeneity and
acquired resistance to achieve more durable clinical responses. In an effort to capitalize on drugs that are
approved and show patient benefit, this proposal seeks to identify compounds that can sensitize cells to
apoptosis when combined with one of three drugs that act as cornerstones in ovarian cancer therapy:
carboplatin, the PARP inhibitor olaparib, and doxorubicin. In the first aim a novel high-throughput screening
platform called high-throughput dynamic BH3 profiling, will be used to identify whether a 24-hour ex vivo
chemical treatment sensitizes tumor cells to mitochondrial mediated apoptosis. This will be performed using
three ovarian cancer models: (1) freshly isolated tumor cells from primary patient ascites fluid, (2) organoid
cultures derived from primary tumors, and (3) ovarian tumor cell lines. Preliminary data indicates that BH3
mimetics in combination with the standard of care drugs can increase apoptotic induction. In the second aim,
the mechanism of drug-induced BH3 mimetic sensitivity will be investigated on the cellular, mitochondrial, and
molecular level to determine which cellular contexts are likely to benefit from specific BH3 mimetic
combinations. In the third and final aim compounds identified that increase apoptotic induction in combination
with each of the three standard of care drugs will be tested in recently developed patient-derived luciferized
tumor xenograft models of ovarian cancer. This will provide in vivo validation of the ability of specific drug
combinations to cause tumor regression. This innovative approach offers both the potential to identify effective
combinations to use in the platinum-sensitive, PARP-sensitive, and platinum-resistant settings, and the
opportunity to determine molecular features that can identify populations that would benefit from these
combinations. Supplementing the research component of the proposal with select courses and workshops,
engagement in research meetings and seminars, and participation in scientific conferences will ensure an
understanding of current concepts and techniques, constant feedback regarding the project's results and
progress, and enhanced exposure to more translational work. Collectively, the research and training plan will
provide a strong foundation upon which to build a career as a productive, independent cancer researcher.
项目摘要/摘要
卵巢癌是女性癌症死亡的第五大原因。最新的估计
预计今年将诊断出2万多例新病例,近14,000名妇女将死于
仅在美国就有2019年的疾病。以铂为基础的标准护理细胞毒性方案在很大程度上仍然存在
在过去的15年里一直停滞不前,而且复发的疾病往往对铂类药物具有抗药性。尽管最近有一些
成功地使用了分子靶向药物和维持疗法(如PARP抑制剂),基因
复杂性和缺乏共同的分子驱动因素使得预测患者的反应变得困难。此外,在
对于复发患者,癌症治疗引起的分子变化是多方面的。多种药物联合应用
治疗卵巢癌可能是克服这种肿瘤内异质性的最直接途径
获得性耐药性,以实现更持久的临床反应。为了努力利用那些
这项提议获得批准并显示出对患者的好处,旨在确定能够使细胞对
与卵巢癌治疗中起基石作用的三种药物之一联合使用时,细胞凋亡:
卡铂、PARP抑制剂奥拉帕利和阿霉素。在第一个目标中,一种新的高通量筛选
该平台名为高通量动态BH3图谱,将用于鉴定是否24小时体外
化学治疗使肿瘤细胞对线粒体介导的细胞凋亡敏感。这将使用以下工具执行
三种卵巢癌模型:(1)从原发患者腹水中新分离的肿瘤细胞;(2)有机物
来源于原发肿瘤的培养;(3)卵巢肿瘤细胞系。初步数据显示,BH3
模拟药物与标准护理药物相结合可以增加对细胞凋亡的诱导。在第二个目标中,
药物诱导的BH3模拟敏感性的机制将从细胞、线粒体和
分子水平,以确定哪些细胞环境可能受益于特定的BH3模拟物
组合。在第三个也是最后一个目标中,化合物被确定为联合增加细胞凋亡的诱导。
与三种标准的护理药物中的每一种都将在最近开发的患者衍生的荧光素中进行测试
卵巢癌异种移植瘤模型的建立。这将为特定药物的体内能力提供验证
联合用药会导致肿瘤消退。这种创新的方法既提供了确定有效的
用于铂敏感、PARP敏感和抗铂设置的组合,以及
有机会确定分子特征,以确定将从这些活动中受益的种群
组合。通过精选课程和讲习班补充提案的研究部分,
参加研究会议和研讨会以及参加科学会议将确保
对当前概念和技术的理解,对项目结果的持续反馈,以及
进步,以及更多地接触到更多的翻译工作。总体而言,研究和培训计划将
提供坚实的基础,在此基础上建立一个多产的,独立的癌症研究人员的职业生涯。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kelley McQueeney其他文献
Kelley McQueeney的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kelley McQueeney', 18)}}的其他基金
Identifying Combination Therapies in Ovarian Tumors using High Throughput Dynamic BH3 Profiling
使用高通量动态 BH3 分析确定卵巢肿瘤的联合疗法
- 批准号:
10534744 - 财政年份:2020
- 资助金额:
$ 6.98万 - 项目类别:
相似海外基金
Development of decellularized small-diameter arterial grafts and evaluation in large animal experiments
脱细胞小直径动脉移植物的研制及大动物实验评价
- 批准号:
21H03016 - 财政年份:2021
- 资助金额:
$ 6.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Developing and validating a computational model of the gut microbiota-mucosa interactions to replace and reduce animal experiments
开发和验证肠道微生物群-粘膜相互作用的计算模型,以取代和减少动物实验
- 批准号:
NC/R001707/1 - 财政年份:2018
- 资助金额:
$ 6.98万 - 项目类别:
Training Grant
Developing and validating a computational model of the gut microbiota-mucosa interactions to replace and reduce animal experiments
开发和验证肠道微生物群-粘膜相互作用的计算模型,以取代和减少动物实验
- 批准号:
2103295 - 财政年份:2018
- 资助金额:
$ 6.98万 - 项目类别:
Studentship
Research on the way of information transmission to gain social understanding of animal experiments
动物实验获得社会理解的信息传递方式研究
- 批准号:
16K07080 - 财政年份:2016
- 资助金额:
$ 6.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CDS&E: Modeling the Zebrafish Model Organism Toward Reducing, Refining, and Replacing Animal Experiments
CDS
- 批准号:
1505832 - 财政年份:2015
- 资助金额:
$ 6.98万 - 项目类别:
Standard Grant
Never replicate a successful experiment? Standardization, heterogenization and reproducibility in animal experiments
从未复制过成功的实验?
- 批准号:
283089959 - 财政年份:2015
- 资助金额:
$ 6.98万 - 项目类别:
Research Grants
Arrhythmogenic Drug Evaluation System by Simplified Animal Experiments
简化动物实验的致心律失常药物评价系统
- 批准号:
26350520 - 财政年份:2014
- 资助金额:
$ 6.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promotion of the 4Rs in animal experiments by the development of a production process for polyclonal antibodies using a goldfish
开发金鱼多克隆抗体生产工艺,促进动物实验中的4R
- 批准号:
23650227 - 财政年份:2011
- 资助金额:
$ 6.98万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of microangiographic systems to visualize cerebular perforating artery in clinical settings and retrobulbar ophthalmic artery arteries in animal experiments.
开发显微血管造影系统,以在临床环境中可视化小脑穿支动脉,并在动物实验中可视化球后眼动脉。
- 批准号:
23390305 - 财政年份:2011
- 资助金额:
$ 6.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
The study for the modification of cerebral synapses by balance exercises in the elderly based on animal experiments.
基于动物实验的老年人平衡运动改变大脑突触的研究。
- 批准号:
21500471 - 财政年份:2009
- 资助金额:
$ 6.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)